Anticonvulsant agents

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 425-447

  Leeder, J Steven ^a   Pirmohamed, Munir ^b  

^a Children's Mercy Hospital   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056677830     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (135)

1. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group [see comments]. Lancet 1999; 354:13-19.
2. Stricker BHC. Drug-Induced Hepatic Injury. Amsterdam: Elsevier Science Publishers, 1992.
3. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 28:S64-S70.
4. Askmark H, Wiholm B. Epidemiology of adverse drug reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990; 81:131-140.
5. Dpssing M, Andreasen PB. Drug-induced liver disease in Denmark: an analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982; 17:205-211.
6. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232:133-138.
7. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82:1826-1832.
8. Pirmohamed M, Park BK. Cytochromes P450 and liver injury. In: RG Cameron, G Feuer, F de la Iglesia, eds. Drug-Induced Hepatotoxicity. Vol. 121. Berlin: Springer-Verlag, 1996: 341-366.
9. Hadzic N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. Arch Dis Child 1990; 65:315-317.
10. Williams RJ, Ruppin DC, Grierson JM, Farrell GC. Carbamazepine hepatitis: the clinicopath-ological spectrum. J Gastroenterol Hepatol 1986; 1:159-168.
11. Levander HG. Granulomatous hepatitis in a patient receiving carbamazepine. Acta Med Scand 1980; 208.
12. Hopen G, Nesthus I, Laerum OD. Fatal carbamazepine-associated hepatitis: report of 2 cases. Acta Med Scand 1981; 210:333-335.
13. Soffer EE, Taylor RJ, Bertram PD, Hagitt RC, Levinson MJ. Carbamazepine-induced liver injury. South Med J 1983; 76:681-683.
14. Larrey D, Hadengue A, Pessayre D, Choudat L, Degott C, Benhamou JP. Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987; 32:554-557.
15. Cox NH, Johnston SRD, Marks J, Bates D. Extensive carbamazepine eruption with eosino-philia and pulmonary infiltrate. Postgrad Med J 1988; 64:249-250.
16. Fellows WR. A case of aplastic anemia and pancytopenia with tegretol therapy. Headache 1969; 9:92-95.
17. Ponte CD. Carbamazepine-induced thrombocytopenia, rash, and hepatic dysfunction. Drug Intell Clin Pharm 1983; 17:642-644.
18. Imai H, Nakamoto Y, Hirokawa M, Akihama T, Miura AB. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron 1989; 51:405-408.
19. Levy M, Goodman MW, Van Dyre J, Summer HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981; 95:64-65.
20. Mitchell MC, Boitnott JK, Arregui A, Maddrey WC. Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 1981; 71:733-735.
21. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another case of the vanishing bile duct syndrome. Gastroenterology 1992; 102:1385-1388.
22. Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32:741-749.
23. Zimmerman HJ, Ishak KG. Antiepileptic drugs. In: RG Cameron, G Feuer, F de la Iglesia, eds. Drug-Induced Hepatotoxicity. Vol. 121. Berlin: Springer-Verlag, 1996:637-662.
24. Farrell GC. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone, 1994.
25. Murphy JV, Francisco CB, Roberts C. Fatal hepatorenal failure in 3 patients receiving carbamazepine. Ann Neurol 1991; 30:276-277.
26. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamaze-pine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82:110-115.
27. Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360-367.
28. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33:183-186.
29. Riley RJ, Smith G, Wolf CR, Cook VA, Leeder JS. Human anti-endoplasmic reticulum antibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem Biophys Res Commun 1993; 191:32-40.
30. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996; 49:234-243.
31. Horowitz S, Patwardhan R, Marcus E. Hepatotoxic reactions associated with carbamazepine therapy. Epilepsia 1988; 29:149-154.
32. Shear NH, Bhimji S. Pharmacogenetics and cutaneous drug reactions. Semin Dermatol 1988; 8:219-226.
33. Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med J 1999; 75:680-681.
34. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4:142-153.
35. Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995; 50:1353-1359.
36. Pirmohamed M, Lin K, Chadwick D, Park BK. TNF-alpha promoter region gene polymorphisms in carbamazepine hypersensitive patients. Neurology 2001; 56:890-896.
37. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carba-mazepine in vitro. Biochem Pharmacol 1992; 43:1675-1682.
38. Tybring G, von Bahr C, Bertilsson L, Collste H, Glaumann H, Solbrand M. Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab Dispos 1981; 9:561-564.
39. Eichelbaum M, Thomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokin 1985; 10:80-90.
40. Kroetz DL, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther 1993; 53:306-315.
41. Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996; 24:469-479.
42. Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos 1982; 10:1-10.
43. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver micro-somes. Biochem Pharmacol 1992; 44:2307-2314.
44. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-1979.
45. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early-stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994; 47:355-360.
46. Lillibridge JH, Amore BM, Slattery JT, Kalhorn TF, Nelson SD, Finnell RH, Bennett GD. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 1996; 24:509-514.
47. Ju C, Uetrecht JP. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 1999; 288:51-56.
48. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39(suppl 7):S8-S16.
49. + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462-472.
50. Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130:598-604.
51. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. Br Med J 1998; 316:1295-1298.
52. Isojarvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35:1217-1220.
53. Jensen NO, Dam M, Jakobsen K. Oxcarbazepine in patients hypersensitive to carbamazepine. Irish J Med Sci 1986; 155:297.
54. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34:163-165.
55. Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29:1480-1485.
56. Mullick FG, Ishak KG. Hepatic injury associated with diphenylhydantoin therapy: a clinico-pathological study of 20 cases. Am J Clin Pathol 1980; 74:442-452.
57. Park BK, Wilson AC, Kaatz G, Ohnhaus EE. Enzyme induction by phenobarbitone and vitamin K1 disposition in man. Br J Clin Pharmacol 1984; 18:94-97.
58. Aiges HW, Daum F, Olson M, Kahn E, Teichberg S. The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J Pediatr 1980; 97:22-26.
59. Flowers FP, Araujo OE, Hamm KA. Phenytoin hypersensitivity syndrome. J Emerg Med 1987; 5:103-108.
60. Egertonvernon JM, Fisk MJ, Snell AP. Phenytoin-induced hepatotoxicity. NZ Med J 1983; 96:467-469.
61. Masso JFM, Carrera N, Zabalza R, Bengoechea MG. Phenytoin (diphenylhydantoin) induced hepatotoxicity. Med Clin 1983; 81:320-321.
62. Smythe MA, Umstead GS. Phenytoin hepatotoxicity: a review of the literature. Drug Intell Clin Pharm 1989; 23:13-18.
63. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28(suppl 2):S23-S29.
64. Bryant AE, Dreifuss FE. Hepatotoxicity associated with antiepileptic drug therapy—avoidance, identification and management. CNS Drugs 1995; 4:9-13.
65. Spechler SJ, Sperber H, Doos WG, Koff RS. Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium: the role of bile duct injury. Ann Intern Med 1981; 95: 455-456.
66. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305:722-727.
67. Tomsick RS. The phenytoin syndrome. Cutis 1983; 32:535-537.
68. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155:2285-2290.
69. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91:631-634.
70. Spielberg SP. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc 1984; 43:2308-2313.
71. Kleckner HB, Yakulis V, Heller P. Severe hypersensitivity to diphenylhydantoin with circulating antibodies to the drug. Ann Intern Med 1975; 83:522-523.
72. Spielberg SP, Gordon GB, Blake DA, Mellits ED, Bross DS. Anticonvulsant toxicity in vitro: Possible role of arene oxides. J Pharmacol Exp Ther 1981; 217:386-389.
73. Munns AJ, De Voss JJ, Hooper WD, Dickinson RG, Gillam EMJ. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 1997; 10:1049-1058.
74. Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, Gillam EMJ. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos 2000; 28: 945-950.
75. Komatsu T, Yamazaki H, Asahi S, Gillam EMJ, Guengerich FP, Nakajima M, Yokoi T. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos 2000; 28:1362-1368.
76. Evans WE, Self TH, Weisburst MR. Phenobarbital-induced hepatic dysfunction. Drug Intell Clin Pharm 1976; 10:439-443.
77. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997; 24:245-249.
78. Bourgeois BFD. Valproic acid: clinical use. In: RH Levy, RH Mattson, BS Meldrum, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:633-640.
79. Dreifuss FE. Valproic acid: toxicity. In: RH Levy, RH Mattson, BS Meldrum, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:641-648.
80. Sussman NM, McLain LW. A direct hepatotoxic effect of valproic acid. JAMA 1979; 242: 1173-1174.
81. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982; 2:591-597.
82. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379-385.
83. Scheffner D, König S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29:530-542.
84. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 39:201-207.
85. Konig SA, Siemes H, Blaker F, Boenigk E, Groß-Selbeck G, Hanefeld F, Haas N, Kohler B, Korinthenberg R, Kurek E, Lenard H-G, Penin H, Penzien JM, Schünke W, Schultze C, Stephani U, Stute M, Traus M, Weinmann H-M, Scheffner D. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994; 35:1005-1015.
86. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46:465-469.
87. Kay JDS, Hilton-Jones D, Hyman N. Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 1986; 2:1283-1284.
88. Eadie MJ, McKinnon GE, Dunston PR, McLaughlin D, Dickinson RG. Valproate metabolism during hepatotoxicity associated with the drug. Q J Med 1990; 284:1229-1240.
89. Tokatli A, Coskun S, Cataltepe S, Ozalp I. Valproate-induced lethal hyperammonemic coma in a carrier of ornithine transcarbamylase deficiency. J Inher Metab Dis 1991; 14:836-837.
90. Honeycutt D, Callahan K, Rutledge L, Wans B. Heterozygotic ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate treatment. Neurology 1992; 42:666.
91. Suchy FJ, Balistreri WF, Buchino JJ, Sondheimer JM, Bates SR, Kearns GL, Stull JD, Bove KE. Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 1979; 300:962-966.
92. Kondo T, Kaneko S, Otani K, Ishida M, Hirano T, Fukushima Y, Muranaka H, Koide N, Yokoyama M. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 1992; 33:172-177.
93. Anderson GD, Acheampong AA, Wilensky AJ, Levy RH. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 1992; 33:736-742.
94. Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 1985; 145:69-76.
95. Krahenbiihl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995; 37:140-143.
96. Li J, Norwood DL, Mao L-F, Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry 1991; 30:388-394.
97. Ponchaut S, Draye JP, Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations: relevance of CoA sequestration to the observed inhibitions. Bio-chem Pharmacol 1992; 43:2435-2442.
98. Bjorge SM, Baillie TA. Inhibition of medium-chain fatty acid ß-oxidation in vivo by valproic acid and its unsaturated metabolite, 2-w-propyl—4-pentenoic acid. Biochem Biophys Res Commun 1985; 132:245-252.
99. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4:1143-1152.
100. Granneman GR, Wang SI, Kesterson JW, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 1984; 4:1153-1158.
101. Kingsley E, Gray PD, Tolman KG, Tweedale R. The toxicity of the metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol 1983; 23:178-185.
102. Rettenmeier AW, Prickett KS, Gordon WP, Bjorge SM, Chang SL, Levy RH, Baillie TA. Studies on the biotransformation in the perfused rat liver of 2-w-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 1985; 13:81-96.
103. Baillie TA. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-w-propyl-4-pentenoic acid. Chem Res Toxicol 1988; 1:195-199.
104. 4-VPA, a toxic metabolite of valproic acid. Science 1987; 235:890-893.
105. Sadeque AJM, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283:698-703.
106. Levy RH, Rettemeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, Acheampong A, Tor J, Guyot M, Loiseau P. Effect of polytherapy with phenytoin, carbamazepine, and stirpentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48:225-235.
107. Donato MT, Gomez-Lechon MJ, Castell JV. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos 1995; 23:553-558.
108. Chang TKH, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57:1946-1954.
109. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-213.
110. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281:577-592.
111. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 1997; 44:55-77.
112. Shen DD, Pollack GM, Cohen ME, Duffner P, Lacey D, Ryan-Dudek P. Effect of age on the serum metabolite pattern of valproic acid in epileptic children. Epilepsia 1984; 25:674.
113. Kochen W, Schneider A, Ritz A. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr 1983; 141:30-35.
114. Paganini M, Zaccara G, Moroni F, Campostrini R, Bendoni L, Arnetoli G, Zappoli R. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid. Eur J Clin Pharmacol 1987; 32:219-222.
115. Tennison MB, Miles MV, Pollack GM, Thorn MD, Dupuis RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 1988; 29:543-547.
116. Siemes H, Nau H, Schultze K, Wittfoht W, Drews E, Penzien J, Seidel U. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993; 34:332-346.
117. Fromenty B, Pessayre D. Inhibition of mitochondrial ß-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67:101-154.
118. Kassahun K, Farrell K, Abbott FS. Identification and characterization of the glutathione and A-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 1991; 19:525-535.
119. Kassahun K, Abbott FS. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene-VPA and its analogue 4-pentenoic acid. Drug Metab Dispos 1993; 21:1098-1106.
120. Gopaul SV, Farrell K, Abbott FS. Identification and characterization of A-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 2000; 28:823-832.
121. Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38:1261-1264.
122. Pellock JM. Felbamate. Epilepsia 1999; 40(suppl 5):S57-S62.
123. O’Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46:1457-1459.
124. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylproprionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9:1225-1229.
125. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercap-turic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997; 10:457-462.
126. Thompson CD, Barthen MT, Hopper DW, Miller TA, Quigg M, Hudspeth C, Montouris G, Marsh L, Perhach JL, Sofia DR, Macdonald TL. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 1999; 40:769-776.
127. Buchanan N. Lamotrigine: clinical experience in 200 patients with epilepsy with follow-up to four years. Seizure 1996; 5:209-214.
128. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology 1996; 46:240-242.
129. Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51:1172-1175.
130. Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. Br Med J 1995; 311:292.
131. Arnon R, DeVivo D, Defelice AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol 1998; 18:251-253.
132. Sachs B, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195:60-64.
133. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33:511-513.
134. Brody MJ. Lamotrigine. Lancet 1992; 339:1397-400.
135. Maggs JL, Naisbitt DJ, Tettey JNA, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000; 13:1075-1081.